Literature DB >> 7819153

Bias in somatic hypermutation of human VH genes.

R A Insel1, W S Varade.   

Abstract

Translationally silent mutations, which are not antigen selected, of human VH6 Ig gene rearrangements isolated from human spleen were analyzed for bias to gain insight into intrinsic features of the mutation process. Sixty-three clones representing 38 VH6DJ rearrangements had an overall mutation frequency of 4.5%, a replacement/silent (R/S) mutation ratio of 2.1 and 167 unique silent mutations. The silent mutations showed bias in: (i) targeting to CDR1 and CDR2, (ii) an increased frequency of mutations of A compared to T nucleotide bases on the coding strand, and (iii) an increased frequency of transitions versus transversions. Bias of C-->G over C-->A, of G-->C over G-->T and of A-->C over A-->T transversions was also present. Hot spots of mutation were observed, some which corresponded to potential sites of stem-loop formation. The results suggest that the somatic mutation process in man may be targeted to the complementarity determining region for some V genes, exhibits specific base substitutions favoring transitions and specific types of transversions, and may be occurring on only one DNA strand.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7819153     DOI: 10.1093/intimm/6.9.1437

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  9 in total

Review 1.  Evolution and the molecular basis of somatic hypermutation of antigen receptor genes.

Authors:  M Diaz; M F Flajnik; N Klinman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-01-29       Impact factor: 6.237

2.  Induction of Ig somatic hypermutation and class switching in a human monoclonal IgM+ IgD+ B cell line in vitro: definition of the requirements and modalities of hypermutation.

Authors:  H Zan; A Cerutti; P Dramitinos; A Schaffer; Z Li; P Casali
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

3.  Deficiency of somatic hypermutation of immunoglobulin G transcripts is a better predictor of severe respiratory tract infections than lack of memory B cells in common variable immunodeficiency.

Authors:  Lone Schejbel; Hanne Marquart; Vagn Andersen; Henrik Permin; Pernille Andersen; Arne Svejgaard; Torben Barington
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

4.  Impact of age on hypermutation of immunoglobulin variable genes in humans.

Authors:  K Rosner; D B Winter; C Kasmer; G L Skovgaard; R E Tarone; V A Bohr; P J Gearhart
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

Review 5.  Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies.

Authors:  Pauline A van Schouwenburg; Simone Kruithof; Christian Votsmeier; Karin van Schie; Margreet H Hart; Rob N de Jong; Esther E L van Buren; Marieke van Ham; Lucien Aarden; Gertjan Wolbink; Diana Wouters; Theo Rispens
Journal:  J Biol Chem       Date:  2014-10-17       Impact factor: 5.157

6.  B lymphocytes of xeroderma pigmentosum or Cockayne syndrome patients with inherited defects in nucleotide excision repair are fully capable of somatic hypermutation of immunoglobulin genes.

Authors:  N Kim; K Kage; F Matsuda; M P Lefranc; U Storb
Journal:  J Exp Med       Date:  1997-08-04       Impact factor: 14.307

7.  Inherent properties of somatic hypermutation as revealed by human non-productive VH6 immunoglobulin rearrangements.

Authors:  W S Varade; J A Carnahan; P D Kingsley; R A Insel
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

8.  Somatic mutation of immunoglobulin V(H)6 genes in human infants.

Authors:  J Ridings; L Dinan; R Williams; D Roberton; H Zola
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

9.  Somatic mutation of human immunoglobulin V genes in the X-linked HyperIgM syndrome.

Authors:  Y W Chu; E Marin; R Fuleihan; N Ramesh; F S Rosen; R S Geha; R A Insel
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.